NDAINJECTIONINJECTABLEPriority Review
Approved
Dec 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 7m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ETHYOL (amifostine) is an intravenous cytoprotective agent approved in 1995 that reduces chemotherapy and radiation-induced toxicities in cancer patients. It is a prodrug that is converted to an active free thiol compound in tissues, providing selective protection to normal cells over tumor cells. The mechanism involves scavenging free radicals and binding to reactive metabolites of chemotherapy agents.
LOE Approaching
Moderate competitive pressure (30/100) indicates a niche market with limited growth opportunities; expect smaller commercial teams focused on retention and cost management.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
A Study of Amifostine (Ethyol) in Patients With Colorectal Cancer
Started Oct 2006
4 enrolled
Colorectal Cancer
Randomized Amifostine For SCCHN
Started May 2003
58 enrolled
Chemotherapeutic Agent ToxicityHead and Neck CancerMucositis+2 more
Amifostine in Treating Patients With Advanced Myelodysplastic Syndrome
Started Aug 1997
36 enrolled
Myelodysplastic Syndromes
Career Relevance
Working on ETHYOL offers limited career growth due to zero linked job postings and approaching loss of exclusivity, making this a niche assignment primarily suited for portfolio management and cost containment experience. This role is best suited for professionals seeking specialized oncology support expertise rather than career acceleration.
Worked on ETHYOL at Fosun Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.